# 2022 Impact Report



# Your impact in 2021/2022

To those who supported Lung Foundation Australia during FY2O22, thank you. The funds you allocated to our programs, the personal donations you made, and the hours you contributed to supporting our services had a real and significant impact on the lives of Australians living with lung disease and lung cancer. Some of the tangible, positive outcomes we achieved across the year with your help are outlined below.

# Supporting patients and carers

**3,166** health-related enquiries received by our Information and Support Centre.





people visited our website for information and support.

**1,002** people connected to peer support.





**36** new information resources developed.

**767** people connected with our nurse services and social worker service.





**37** Lungs in Action exercise programs delivered.

# Raising lung health awareness

**4,749** earned media stories about lung health published, with **981 million** impressions.

0= 0= 0= 0=	$\Big]$
•	J

**87,717** people completed our online Lung Health Checklist.

# Driving research



**\$12 million+** raised or pledged to our Hope Research Fund.

12 Hope Research Fund partnership **grants** awarded.





**3 collaborations** with research institutions.

# Optimising patient care

**10,711** health professionals engaged.





**3,801** registrations for health professional learning.

**26** clinical committees and networks involved.





**173,554** views of our 2 clinical toolkits.

**39** Lungs in Action Instructors trained.

		<u>^</u>		
ſ	-	=		
l	-	Ξ	•	။ ဂ
l		_		1

# Championing change

Recognised as the peak body for lung conditions by the Australian Government Department of Health.





made to advocate for prevention, early detection, treatment, support and care.

**100+** meetings held with consumer advocates, members of parliament and senators.

2





# 3 Specialist Lung Cancer Nurses and

a **Respiratory Care** Nurse in South

**Australia.\*** \*Funded by South Australian Government.

# \$20 million

Commonwealth funding for a Chronic Respiratory Health Conditions Research Grant.



Australian Government funding for a

# National Silicosis Prevention Strategy

and Action Plan.

# Contents

Your impact in 2021/2022	2
Welcome	4
About us	5
Lana's story	6
The facts	7
Hope through research	8
Support through the journey	10
On-the-ground support and care	11
Driving early diagnosis	12
Optimising patient care	13
Supporting mental health	14
Our team and culture	16
Our governance	17
Our supporters	18
Financials	20
How you can support us	24



#### Acknowledgement of Country

Lung Foundation Australia acknowledges Australia's Aboriginal and Torres Strait Islander peoples and pays respect to their Elders, past, present and emerging. We do so in a spirit of reconciliation, recognising that Aboriginal and Torres Strait Islander peoples across Australia are significantly overrepresented in lung disease and lung cancer. We commit to partnering with communities to address this and Close the Gap.

# Welcome from CEO and Chair

At Lung Foundation Australia, we remain dedicated to our Mission and Vision of bringing hope to the one in three Australians living with or impacted by lung disease or lung cancer. We are Australia's oldest and most trusted lung disease and lung cancer charity. Over the past year, we have continued to experience growth in terms of the number of people we support, our influence, and the amount of funding that we generate.

People with lung disease and lung cancer are at the heart of all that we do, and our work covers a wide spectrum of lung diseases and lung cancer. We are ideally positioned to support people with chronic lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis; those living with rare lung diseases such as pulmonary fibrosis and pulmonary arterial hypertension; people with lung cancer; and those diagnosed with re-emerging occupational lung diseases such as silicosis.

Lung disease impacts all Australians in some way over their life spans. Across the year, our work improving lung health for all was significantly boosted by funding through the Commonwealth's Health Peak Advisory Bodies Program. This injection of funds allowed us to extend our work in preventive lung health including lung cancer screening, immunisation, smoking cessation, and education around e-cigarettes and vaping.

The past 12 months have also seen our models of care grow substantially. We received a funding commitments to help establish new Lung Foundation Australia Specialist Lung Cancer Nurses in hospitals, and we established a new telephone social worker service. We delivered a more prominent Lungs in Action program in response to limited pulmonary rehabilitation opportunities, as well as new models for individual and group support via our Peer Support program.

Together with Thoracic Society of Australia and New Zealand and Asthma Australia we launched the Lung Learning Competency Framework for Primary Health Care to improve early diagnosis and treatment for lung diseases.

Meanwhile, the Hope Research Fund that we launched in 2021 has continued to flourish. It forms the cornerstone of our commitment to lung health research, and throughout the year it tracked ahead of our donor and major-gift targets. This generosity on the behalf of donors has allowed us to invest millions in four research pillars. These are early and mid-career PhDs and fellowships, mid-sized innovation incubator grants, and large-scale multiyear strategic partnership grants. The fund continues to grow and fill the void left by decades of under investment in lung health research by governments.

Our work also continues to improve awareness of lung diseases and to fight against the stigma attached to these conditions – something which has unfairly stifled empathy for people living with lung disease or lung cancer.

We are continuing to advocate to all levels of government for a national, targeted lung cancer screening program, a national air-quality strategy, and for improved care for patients, including access to the right treatments at the right time. Looking forward, we are carefully monitoring the effects of COVID-19 to ensure that we are as well placed as possible to support the growing number of Australians who are experiencing long-term impacts.

Our financial position remains strong, and we continue to attract new opportunities and supporters. The Lung Foundation Australia Board is very appreciative of the trust that you place in us and for the tangible difference you make through your financial support.

We hope that you will continue to support our work to ensure that all Australians have hope in every breath.

Professor Lucy Morgan Chairperson

Mark Brooke Chief Executive Officer



# About us

Lung Foundation Australia is the only charity and leading peak body of its kind in Australia that funds groundbreaking research and delivers life-changing support services that give hope to families impacted by lung disease or lung cancer. Since 1990, we have been working to ensure lung health is a priority for all by promoting lung health and early diagnosis, advocating for policy change and research investment, raising awareness about the symptoms and prevalence of lung disease and championing equitable access to treatment and care.

# **Our Vision**

Lung Foundation Australia enables life-saving lung health and lung cancer research and champions programs so that Australians with lung disease and lung cancer can live their best life.

# **Our Mission**

By 2030, Lung Foundation Australia will be recognised as one of the world's most innovative and effective lung health charities and a fearless leader of lung health and lung cancer policy, programs and research.

### **Our Values**

**Bold** Be proactive and take risks that achieve our Mission.

**Entrepreneurial** | Be focused on outcomes.

**Fair** Be equitable and work in the interests of all our stakeholders, particularly patients and their carers.

**Agile** Create positive change.

**Innovative** Be inventive to achieve our Mission.

**Respectful** Be honest and work hard every day in every way - we are funded by the community, they should expect nothing less.

# Our Strategy

Lung Foundation Australia has just completed the third year of its five-year Corporate Strategy. Building on the substantial growth we achieved over the past three years through our 'Accelerate' phase, the next phase we will embark on is 'Transformation'. This will see our combined energy focused on a range of goals, including service impact and sustainable growth using digital technologies to enhance engagement and reach. We will work to increase our equity position through increased government investment, more philanthropic and corporate giving, and by cementing our role as Australia's most trusted lung health and lung cancer charity.

We continue to grow our organisational footprint, impact and headcount, while ensuring that our processes and systems are future-focused and fit for purpose. Under new Chairperson Professor Lucy

Morgan, the Board is working on a renewal process that aligns the capabilities of the Board and its various subcommittees. The Board has invested in new technologies related to risk management, compliance, finance and budgeting, grants management and process development.

Scan to view the strategy.



# Lana's story

Lana was a young, fit and healthy 30-year-old when she started to experience strange back pain.

"I was super healthy," she remembers. "I was going to gym every morning. Then, in June 2019 I started getting this weird back pain and it just wouldn't stop. I asked the doctor for a scan and he was very dismissive and just said, 'Have you tried mindfulness?"

Lana was eventually referred for a scan six months later. She was subsequently diagnosed with stage IV lung cancer.

Lana began treatment soon after and despite responding well with no further growth in her lung, the cancer spread to her brain.

"It can be really hard hearing that you will most likely be around for two to three years, given the rarity of your cancer" she says. "Or even if you want to get to your 35th birthday or 40th, it'll be a medical miracle. But once you get used to that and find the right supports, especially for me, you just want to help people, so that they're not in the same situation that you are in."

After her diagnosis Lana felt as though she had no direction, no purpose. However, through Lung Foundation Australia, she found a way that she could support others like herself. "When I found Lung Foundation Australia it was such a relief," she says. "I thought 'now I can help others through advocacy'. It's shocking just how unjust the current system is."



Due to support from my doctors, my family, friends and also the Lung Foundation Australia, I'm still here. Lana's drive to help others is something that she attributes to being an older sister. "I love connecting with people and helping them in any way that I can, even if that something involves me doing things like public speaking that I'm terrified of. If it's helping somebody else, I do not care. I know that that's what I'm here to do."

Lana is a member of Lung Foundation Australia's Lung Cancer Consumer Advisory Committee and is a strong and vocal advocate. She is passionate about using her voice to champion change and improve outcomes for Australians with lung cancer. From meeting with politicians in Parliament to speaking to media, Lana continues to raise awareness about the impact of lung cancer in Australia.

"I'm in a good spot right now," she says. "I'm feeling really good, really healthy. Due to support from my doctors, my family, friends and also the Lung Foundation Australia, I'm still here."

Scan to read more of Lana's story.







**1 in 3** Australians are impacted by lung disease or lung cancer.

Approximately **43** families lose a loved one every day.

Lung disease accounts for 9% of total disease burden in Australia, yet only receives 2% of research investment.



**Stigma** remains a **major barrier** to people accessing research, treatment and support.



Australians are diagnosed with lung cancer every day.



**COPD is the #1** cause of potentially preventable hospitalisations.

Air pollution accounts for 3,000 premature deaths each year.





Between **83,000** and **103,000** silicosis cases are expected from current **workplace exposure.** 

Young Australians who vape are **18x more likely** to try cigarette smoking and **3x more likely** to be a regular smoker.



# Hope through research

For the millions of Australians impacted by lung disease and lung cancer, research means hope. Hope for more precious moments with loved ones, a chance to experience that next life milestone and independence to do day-to-day activities.

Lung Foundation Australia's comprehensive research program is revolutionising our understanding of these conditions. It encompasses a multi-milliondollar grants and awards program, internationally renowned registries and impactful research partnerships. This program is made possible through the generosity of community supporters, corporate partners and major gifts.

# Hope Research Fund

Launched in 2021, Lung Foundation Australia's Hope Research Fund is a 10-year initiative that invests in life-changing lung disease and lung cancer research. With the help of our generous community, we are working to raise \$50 million by 2030 to accelerate ground-breaking research that will save lives.

(	\$10m	\$20m	\$30m	\$40m	\$50m )

#### \$12m donated towards \$50m goal

# A legacy of hope

Laxmi Vanza always maintained a positive outlook on life. In 2011, Laxmi's family was shocked when she was diagnosed with both breast cancer and pulmonary fibrosis. Despite treatment, Laxmi's lung fibrosis progressed over the next 10 years and she sadly passed away, leaving behind her husband, two sons, and four grandchildren.

Laxmi was someone who gave all that she could to help those in need, and her family have honoured her legacy by supporting a research grant in her name. Delivered through the Hope Research Fund, the Laxmi Vanza Grant for Innovation in Idiopathic

Pulmonary Fibrosis Research is valued at \$10,000 and will support research into improving outcomes for those impacted by this disease.

The generous support of families like Laxmi's enables us to invest in the best and brightest researchers through the Hope Research Fund.





Scan to watch our Hope Research Fund video.

### Investing in the best and brightest researchers

As part of the Hope Research Fund, our awards and grants program identifies and encourages new, innovative research projects across a broad range of lung disease areas. This research drives a deeper understanding of the causes, prevalence and impacts of lung disease, new methods of diagnosis and opportunities to improve outcomes and quality of life.

Scan to view our 2022 Grant Award **Recipients**.





Research award recipient Dr Arwel Jones and Professor Lucy Morgan, Lung Foundation Australia Chair.

"The funding allows early career researchers like me to have time focused on doing important work in investigating how exercise can boost anti-viral immunity and reduce lung inflammation, to help prevent COPD flare-ups. I cannot proceed with this research without this Scan to read more funding, it is so essential."

- Dr Arwel Jones, recipient of the 2022 Lung Foundation Australia - Boehringer Ingelheim Fellowship in COPD

about Dr Jones' research.



# **Connection to clinical trials**

Lung Foundation Australia is proud to support the Pulmonary Fibrosis Australasian Clinical Trials Network (PACT), which connects patients and clinicians to cutting-edge clinical trials. Find out more at pact.lungfoundation.com.au.

# Data driving research

The internationally recognised Australian IPF Registry has been finalised after 10 years of successful operation. With data collected from 867 generous participants living with IPF, the registry has supported research that has contributed to our increased understanding of this complex disease and ultimately to the improved management and outcomes of IPF patients.

Find out about our Australian Bronchiectasis **Registry and Australasian Interstitial Lung** Disease Registry via our website.

# Partnership grants

Centre of Research Excellence in Pulmonary Fibrosis. \$200,000 over two years as part of a \$1.6m multi-organisation partnership.

Cancer Australia. \$600,000 over four years for early-career research grants through the Prioritydriven Collaborative Cancer Research Scheme.

Heart of Australia. \$50,000 for Occupational Lung Disease screening.

Better Breathing Foundation. \$50,000 for the codesign of a new Pulmonary Rehabilitation Patient Self-Management App.

# Support through the journey

In 2021/2022, over 700 Australians impacted by Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis and lung cancer received personalised support and guidance through our comprehensive nurse-led telephone support service. Our highly experienced nurses provide evidence-based guidance across all stages of an individual's condition, connecting them with relevant services to ensure they have the support they need.

This flagship program demonstrates major impact, with data showing those who utilise the service report significant improvements in managing their condition.

R	R
$\bigcirc$	U

"Lung Foundation Australia's Respiratory Care Nurse walked me through every step arming me with all the information I needed. I have an action plan, vaccinations now up-to-date and have had a respiratory assessment at the hospital and now under a specialist. I wouldn't have known where to start if it wasn't for the nurse. She has been a life raft."

- Patricia, living with COPD

#### **Highlights:**



Reported symptoms and psychological burden were reduced.



Action Plan ownership doubled.

Uptake of pulmonary exercise programs increased significantly.



Uptake of pneumonia vaccination increased.

These nurse telephone services are provided free of charge thanks to the generous support provided by our community and government funders.

Lung Foundation Australia provides life-changing support to thousands of Australian families impacted by lung disease or lung cancer each year. Scan to find out more about our support groups, exercise programs, and telephone support services.



Right to left: Amanda, Nicole and Jilian, Lung Foundation Australia's nurses.

# On the ground support and care

Research shows having access to a specialist cancer nurse can significantly improve an individual's health outcomes. However, the number of specialist lung cancer nurses in Australia has long lagged behind the number of nurses available for many other forms of cancer.

In response to ongoing campaigning by Lung Foundation Australia and our consumer community, the Commonwealth Government announced milestone pilot funding for four Lung Foundation Australia Specialist Lung Cancer Nurses (SLCN). The nurses, who have begun work in New South Wales' Illawarra Shoalhaven Local Health District, form the foundation of a first-of-its-kind demonstration project aimed at highlighting the benefit of such care.

Additionally, the South Australian Government has funded three SLCNs, increasing the number of dedicated nurses nationwide to 48.

These nurses will work to address the inequities faced by people in their communities who are living with lung cancer, from diagnosis through to palliative care, providing information and education throughout each person's treatment.

# This is a positive first step toward increasing the number of SLCNs in Australia to our goal of 100 nurses by 2025.



Lung Foundation Australia's Lung Cancer Support Nurse (LCSN) telephone service will complement the care that people with lung cancer receive from SLCNs. This will provide them with the holistic support they deserve, and ultimately improve their overall outcomes.

# Increasing respiratory care

Lung Foundation Australia is committed to improving access to best-practice treatment and support for all lung conditions.

In conjunction with the funding for SLCNs, our campaigning efforts led to the South Australian government funding a Respiratory Care Nurse (RCN). RCNs can assist in care for over 30 types of lung diseases, including COPD. In South Australia, COPD was the 5th leading cause of death in 2018, and second-leading cause of avoidable hospital admissions. This role can ultimately reduce the impact COPD has on hospitals and improve quality of life for people living with COPD.



Jilian, Lung Foundation Australia RCN.

# Driving early diagnosis

Thousands of Australians unknowingly dismiss symptoms of lung disease and lung cancer as ageing or a lack of fitness while the disease progresses.

Our national Lung Health Awareness Month Campaign encourages Australians experiencing symptoms to complete an interactive online Lung Health Checklist and to speak to their GP.

In 2022, a reshaping of the campaign with support from our industry partners\* helped us to achieve a remarkable 574% increase in the number of people completing the checklist compared to the previous year. The campaign was expanded to include components that allowed for tailored lead-nurturing and follow-up, and these helped us to achieve direct consumer impact.

As we continue to communicate with those who indicated symptoms, the number of GP visits and diagnoses continues to increase. Those who self-reported a lung-disease diagnosis have been connected to Lung Foundation Australia's information and support services. They will have access to ongoing support in navigating the health system and on their disease journey.

# 66

"Since I did the survey, I have seen a lung specialist and I'm on a better track now. I am having further assessment and testing shortly, but I'm now more confident of a better breathing future."

#### – Glenda



\* **Supported by AstraZeneca.** This Lung Health Awareness Month: Early Diagnosis Campaign is supported by an independent Medical Education Grant provided by Boehringer Ingelheim. Supported by the Australian Government Department of Health.

# **Optimising patient care**

Improved care and accurate diagnosis for people living with a lung disease or lung cancer has a direct impact on quality of life, mental health, reduced hospital admissions and overall prognosis. We are committed to ensuring healthcare professionals across Australia are well placed and well equipped to deliver the levels of care and support our community deserves.

# Lung Learning Framework

Primary care health professionals play a critical role in the early detection of lung disease and lung cancer. The Lung Learning Framework aims to support them in this vital work by providing national best-practice standards for the diagnosis, treatment and care of lung conditions.

The first initiative of its kind for respiratory health in the world, the framework consolidates lung health knowledge and skills across the patient continuum.

The project is funded by the Australian Government Department of Health as part of the National Strategic Action Plan for Lung Conditions. It is a collaborative initiative between three leading lung health organisations, namely Lung Foundation Australia, The Thoracic Society of Australia and New Zealand, and Asthma Australia.

The framework can be used by training providers as a benchmark for the development and review of their education activities. It can also be used by individual health professionals who want to self-appraise their own knowledge and skills. It guides learners and educators to consider, adapt and enhance their skills within lung health in order to deliver best-practice care.

The Lung Learning Framework has underpinned the Lung Learning Hub, a one-stop education and training website for health professionals looking to upskill within respiratory health. The Hub will be available in late 2022.

### Upskilling health professionals

The Lung Learning Framework is just one of the many initiatives we offer to upskill and support health professionals to provide bestpractice care and support to patients. The scope of our health professional education program includes accredited training and education, virtual and on-demand learning sessions, conferences, and professional development events. **Visit our website to find out more.** 

# GG

"This competency-based education framework is world-first in respiratory healthcare. It will revolutionise Australian lung health education and go a long way in improving outcomes for patients."

- Dr Kerry Hancock, GP, Chair of Lung Foundation Australia's Primary Care Clinical Advisory Committee ER PRIMARY HEALTHCARE PROFESSIONAL FOR THOME

# Supporting mental health

# Emotional support at the end of the phone

Launched in February 2022, our Social Work telephone service aims to help people with a diagnosis to navigate the practical and emotional challenges of living with lung cancer. An experienced social worker provides callers with information in areas including the impact on relationship and finances and coping with progression or recurrence. The service highlighted a significant need in the community, with 120 interactions recorded in the first four months of its establishment.

#### Highlights of the service so far:

**40%** reported a decrease in psychological concerns from first to final appointment.

**68%** reported accessing psychological support services.

100% indicated that the service addressed their worries and needs.

# Sue's story

Sue was diagnosed with lung cancer after breaking one of her ribs. The diagnosis was unexpected and left her feeling "shell shocked" for the following six months. In investigating support opportunities, Sue found Lung Foundation Australia's Lung Cancer Social Work service. Our social worker guided Sue on how to get back to the workplace – a task that was causing her anxiety – and armed her with knowledge and suggestions on how to approach the transition.

"I can't speak highly enough of the way the social worker dealt with me and my situation. I felt heard and her gentle approach and knowledge made me feel comforted that I was dealing with a professional. It gave me a sense of support when so much was going on mentally, emotionally and physically."

Scan to read more about the service.





# One-stop shop for mental health support resources

Knowledge is a powerful tool when living with lung disease or lung cancer. The Mind Matters hub on our website brings together a range of useful resources aimed at helping people address the emotional toll of life with a lung condition. Developed in collaboration with experts and consumers, it provides accessible, easy-to-navigate written information on areas such diagnosis, adapting to change, and advice for carers. All resources have been curated to help members of our community prioritise their mental and emotional wellbeing.



#### 17,700+

views on Mind Matters webpages, videos and webinars. Scan to access the Mind Matters Hub.



# Mindfulness and self-compassion video series

In this Mind Matters video, social worker, counsellor and therapist Tracie guides viewers through the self-care practice of 'grounding'. Designed to be accessible and easy to use for people living with a lung condition, the Mind Matters video series shows how to shift the focus away from breath during meditation practices. **To view the full video series, visit lungfoundation.com.au/MindMatters.** 



Scan to watch the video.

# Our team and culture

Our people lie at the core of everything we do. Their passion to make a difference for people with lung disease and lung cancer is what drives us forward. We are committed to investing in and supporting our people and ensuring that we foster a safe and inclusive workplace culture.

The Lung Foundation Australia team is highly committed to both the organisation and our mission. Our annual employment-engagement surveys consistently rate our organisation higher than the industry benchmark in all areas of assessment. Both engagement and belief in the future of the Lung Foundation Australia are rated at 90% by our people.

Our staff have told us that they value the flexible working arrangements that we introduced during COVID-19. We have listened and responded by making flexibility part of the way we work. Meanwhile, to help build relationships, we have created an online Connection Hub where our people can connect socially and celebrate achievements and events. All employees, consumer advocates and committee members have access to emotional and mental health support via our anonymous, independent employee assistance program.

Our people and culture initiatives are informed by our employee-led People and Culture Committee. With representation from every department, the committee meets regularly to review culture, wellbeing and organisational processes and to make recommendations for improvement.





# Our governance

The Lung Foundation Australia Board consists of 10 directors who volunteer their expertise and time to help improve lung health and reduce the impact of lung disease for all Australians.

### **Board members**

**Professor Lucy Morgan**: Chair (Non-Executive) -Director, B.Med PhD, FRACP

**Mr Andrew Churchill**: Deputy Chair (Director), Treasurer - FCA, MAICD

**Professor Christine Jenkins AM** - MB BS (Hons II), MD, FRACP

**Ms Kathleen Cummings** - Director, Grad.Dip in Management (CSU), GAICD

Doctor David Michail - Director, MB BS, FRACP


**Professor Martin Phillips** - Director, BSc, MB BS, MRCP, FRACP

Ms Angela Ratcliffe - Director, GAICD, B.Bus

**Ms Melissa Mesurier** - Director, GAICD, B.Arts (Politics and Journalism)

**Professor Sarath Ranganathan** - Director, MCChB, MRCP, FRCPCH, PhD

**Professor Paul Reynolds** - Director, MB BS PhD, MD, FRACP, FThorSoc



# **Our Supporters**

### Government

Australian Government Department of Health National Health and Medical Research Council NSW Ministry of Health Queensland Health Queensland Stronger Communities Fund Victoria Stronger Communities Fund SA Health

#### **Estates**

Donald Edward Jago Martha Louise Sims Gillian McGimpsey-Evans Andrew John Harrison Antonia Rasen Desmond John Hickey Rehle Cheney Jean Parkin Beverley Mcilwain Margaret Kerec

### **Major Donors**

Bonnie Boezeman Helen and Richard Irving Tony and Gai Wales Lynn Yager Nathalie Quinlivan Brent and Vicki Emmett Janet Hawkins Joan Whyte Logan Martin Martin Baumber Barry and Christine Comben Rabia Manchanda

# Grants, Trusts and Foundations

Scobie and Claire McKinnon Trust Frost Family Endowment Youth Health Forum Dimmick Charitable Trust James Frizelle Charitable Foundation Elaine Walters Foundation Queensland Community Foundation Robert Fergusson Family Foundation The Lyone Foundation John Christopher Pascoe Memorial Fund managed by Perpetual Limited Woodend Foundation

### Corporate Donors and Community Partners

Multiplex De Pasquale Group of Companies Finer Power Transmission PwC Award Force Pty Ltd Kensington Garden Craft Group Freemasons Foundation Victoria Freemasons Spring Vale Lodge Kelly and Windsor Maurice Blackburn Lawyers Philips Healthcare Vocus Communications

### Community Fundraising Partners

Elizabeth Yates Denise Lindsell Fiona Telfer Rebecca Marsh Sarah Latham Anita McGrath Georgia Smith Lorraine Tyler Antonietta Caruana Natasha Paul Maus Grant Trail to Triumph - Ultramarathon for Mesothelioma Jacob Lynch Kane, Tahlia, Kiara and Harper Morris The Cassy Morris Foundation

### **Corporate Partners**

A. Menarini Australia Amgen Australia AstraZeneca Australia Beigene Boehringer Ingelheim Bristol-Myers Squibb Australia Chiesi Australia Cipla GSK Australia Insmed Janssen & Johnson and Johnson Medical Developments International Merck Sharp & Dohme Novartis Pfizer Australia Roche Australia Takeda Zambon

#### Research Collaborations, Universities, and Institutions

Austin Health Curtin University Edith Cowan University La Trobe University Melbourne Health Menzies Research Institute Tasmania Menzies School of Health Research Monash University Newcastle University Queensland University of Technology (QUT) RMIT University Sir Charles Gairdner Hospital Sydney Catalyst Translational Cancer Research Centre The Children's Hospital at Westmead The Garvan Institute for Medical Research University of Newcastle University of South Australia University of South Australia University of Tasmania University of Technology Sydney University of Western Australia Walter & Eliza Hall Institute of Medical Research Woolcock Institute of Medical Research

### Research and Health Partnerships

Australasian Bronchiectasis Consortia Three Lakes Foundation USA Better Breathing Foundation Cochrane Airways Centre of Research Excellence in Pulmonary Fibrosis Centre of Research Excellence - Treatable Traits Thoracic Society of Australia and New Zealand Lung Health Alliance Lung Cancer Clinical Quality Data Platform (LUCAP)

# Financials

I am delighted on behalf of the Board's Finance, Audit and Risk Management (FARM) Subcommittee and the Foundation's Investment Subcommittee to present the Lung Foundation Australia's financial performance as at 30 June 2022. Please note the prior period in the report to 30 June 2021 represents six months of operations due to the change of our financial year end. Our operational deficit for the year of \$222,238 was influenced by delayed bequests. This is a timing issue, and our ongoing financial position remains very strong with growth in government grants revenue a highlight.

Our year end result was heavily impacted by global financial unease late in the financial year. This resulted in a write down due to the decline in unrealised market value of \$1,256,985 since 1 July 2021 for the investments set aside for the Hope Research Fund for Lung Health. Due to this equity decreased to \$6,142,060 from \$7,621,286 the prior year however the market has rebounded in Q1 2023.

The Foundation remains committed to growing the lung health research corpus to \$50 million by 2030 and the Investment Subcommittee continues to advise the Board and ensure the maximum amount is flowing to research activities. With a very strong pipeline of bequests and major gifts the Hope Research Fund invested over \$2.48 million in lung disease and lung cancer research over the financial year.

The Board's ongoing investment in our fundraising and development capacity continues to show results as our grant, sponsorship and donation income increased. Pleasingly the Foundation secured several new multiyear grants including capacity building funding under the Federal Government's Health Peak Advisory Program.

The FARM Subcommittee has carefully monitored our administration and fundraising expenses (9.5% and 16% respectively) to ensure funds for programs, services, lung health awareness and research were maximised.

Acknowledging the ongoing impact of the COVID pandemic and harsher economic indicators the Board and FARM Subcommittee continues to closely monitor our operations to ensure programs and services are keeping pace with community need and fundraising objectives and targets are being met.

I acknowledge the members of both the FARM and Investment Subcommittees for their significant contribution of time and expertise and thank each one, together with our donors and supporters for a very successful year in review.

Andrew Churchill Chairperson FARM and Investment Subcommittees

Scan to view the 2021/2022 financial statements.



Lung Foundation Australia statement of profit or loss and other comprehensive income	12 months to 30 June 2022 [\$]	6 months to 30 June 2021 [\$]
Grants - Government	1,950,348	577,905
Grants - other sources	1,154,320	531,828
Sponsorships	1,963,833	581,007
Donations	1,815,268	927,186
Bequests	1,057,270	2,444,575
Net change in fair value of financial assets classified at fair value through profit or loss	(1,256,985)	612,485
Other income	1,298,407	511,393
Total revenue and other income from continuing operations	7,982,460	6,186,379
Research expenses	2,182,171	908,740
Programs and services expenses	1,602,915	440,790
Employee Expenses	3,784,341	1,572,318
Fundraising expenses	444,706	300,697
Fundraising expenses Marketing expenses	444,706 699,035	300,697 227,269
	·	
Marketing expenses	699,035	227,269
Marketing expenses Other expenses Surplus / (deficit) from continuing operations before finance	699,035 748,515	227,269 450,289

Current assetsCash and cash equivalents771,584870,365Receivables275,261262,675Other current assets238,022239,443Financial assets - Company0781,833Total current assets1,284,8672,154,516Non-current assets8,422,9689,213,031Property, plant and equipment134,405132,580Right of Use Asset347,453522,804Total current assets8,904,8449,868,415Total con-current assets10,189,71112,022,931Total assets10,189,71112,022,931Total assets10,389,71813,1610Income in advance2,095,7872,683,181Contract liabilities2,27129184,325Employee benefits2,27129184,325Lease liabilities3,474,533,694,541Total non-current liabilities3,64,9513,989,539Employee benefits54,77343,679Lease liabilities143,3753,64,421Total non-current liabilities143,3753,64,421Total non-current liabilities143,3753,64,421Total non-current liabilities143,4753,64,213Total lanon-current liabilities143,4753,64,213Total lanon-current liabilities143,4753,64,213Total lanon-current liabilities142,106142,106Total lanon-current liabilities142,106142,106Total lanon-current liabilities142,106142,106 <trr>T</trr>	Lung Foundation Australia statement of financial position As at 30 June 2022	12 months to 30 June 2022 [\$]	6 months to 30 June 2021 [\$]
Receivables275,261262,675Other current assets238,022239,043Financial assets - Company0781,833Total current assets1,284,8672,154,516Non-current assets8,422,9869,213,031Property, plant and equipment134,405132,580Right of Use Asset347,453522,804Total current assets8,904,8449,868,415Total assets10,189,71112,022,931Total assets10,189,71112,022,931Total assets2,095,7872,683,181Current liabilities2,2095,7872,683,181Payables491,745131,610Income in advance2,095,7872,683,181Contract liability787,425785,425Employee benefits2,47,415204,998Total current liabilities3,849,5013,999,539Employee benefits54,77343,679Lease liabilities198,148412,106Total non-current liabilities198,148412,106Total unon-current liabilities198,148412,106Total liabilities198,148412,106Total liabilities198,148442,106Total liabilities198,148442,106Total liabilities40,47,6484,401,645Total liabilities40,47,6484,401,645Total liabilities40,47,6484,401,645Net Assets6,142,0637,621,286	Current assets		
Other current assets238,022239,643Financial assets - Company0761,833Total current assets1284,8672,154,516Non-current assets8,422,9869,213,031Property, plant and equipment134,405132,580Right of Use Asset347,453522,804Total non-current assets3,904,8449,868,415Total non-current assets0,189,71112,022,931Total assets10,189,71112,022,931Current liabilities2,095,7872,683,181Contract liability787,425785,425Employee benefits2,27,129184,325Lease liabilities3,849,5013,989,539Employee benefits3,447,7343,679Lease liabilities143,3753,68,427Total non-current liabilities143,3753,68,427Net Assets6,142,0637,621,286Reity	Cash and cash equivalents	771,584	870,365
Financial assets - Company         0         781,833           Total current assets         1,284,867         2,154,516           Non-current assets         8,422,986         9,213,031           Property, plant and equipment         134,405         132,580           Right of Use Asset         347,453         522,804           Total non-current assets         8,904,844         9,868,415           Total assets         10,189,711         12,022,931           Current liabilities         10,189,711         12,022,931           Payables         491,745         131,610           Income in advance         2,095,787         2,683,181           Contract liabilities         227,129         184,325           Employee benefits         247,415         204,998           Total current liabilities         3,849,501         3,989,539           Employee benefits         54,773         43,679           Icase liabilities         54,773         43,679           Total non-current liabilities         198,148         442,064           Total non-current liabilities         198,148         442,064           Icase liabilities         40,647,648         44,00,645           Total non-current liabilities         40,647,648	Receivables	275,261	262,675
Total current assets         1,284,867         2,154,516           Non-current assets         8,422,986         9,213,031           Property, plant and equipment         134,405         132,580           Right of Use Asset         347,453         522,804           Total assets         8,904,844         9,868,415           Total assets         8,904,844         9,868,415           Total assets         10,189,711         12,022,931           Current liabilities         10,189,711         12,022,931           Payables         491,745         131,610           Income in advance         2,095,787         2,683,181           Contract liabilities         227,129         184,325           Employee benefits         227,129         184,325           Lease liabilities         247,415         204,998           Total current liabilities         3,849,501         3,989,539           Employee benefits         54,773         43,679           Lease liabilities         143,375         368,427           Total non-current liabilities         198,148         412,106           Total non-current liabilities         198,148         412,106           Total non-current liabilities         6,142,063         7,621,286 <td>Other current assets</td> <td>238,022</td> <td>239,643</td>	Other current assets	238,022	239,643
Non-current assets         8,422,986         9,213,031           Property, plant and equipment         134,405         132,580           Right of Use Asset         347,453         522,804           Total non-current assets         8,904,844         9,868,415           Total assets         10,189,711         12,022,931           Current liabilities         10,189,711         12,022,931           Payables         491,745         131,610           Income in advance         2,095,787         2,683,181           Contract liabilities         287,425         785,425           Employee benefits         284,325         184,325           Lease liabilities         247,415         204,998           Total current liabilities         3,849,501         3,989,539           Employee benefits         3,849,501         3,989,539           Employee benefits         54,773         43,679           Lease liabilities         143,375         368,427           Total non-current liabilities         143,375         368,427           Total tubilities         4,047,648         4,401,645           Net Assets         6,142,063         7,621,286           Net Assets         6,142,063         7,621,286	Financial assets - Company	0	781,833
Financial assets       8,422,986       9,213,031         Property, plant and equipment       134,405       132,580         Right of Use Asset       347,453       522,804         Total non-current assets       8,904,844       9,868,415         Total assets       10,189,711       12,022,931 <b>Current liabilities</b> 12,022,931         Payables       491,745       131,610         Income in advance       2,095,787       2,683,181         Contract liabilities       287,425       785,425         Employee benefits       227,129       184,325         Ital current liabilities       3,849,501       3,989,539         Employee benefits       3,849,501       3,989,539         Employee benefits       3,849,501       3,989,539         Employee benefits       3,849,501       3,989,539         Employee benefits       3,849,501       3,989,539         Lease liabilities       143,375       3,68,427         Total non-current liabilities       143,375       3,68,427         Net Assets       6,142,063       7,621,286         Net Assets       6,142,063       7,621,286	Total current assets	1,284,867	2,154,516
Property, plant and equipment         134,405         132,580           Right of Use Asset         347,453         522,804           Total non-current assets         8,904,844         9,868,415           Total assets         10,189,711         12,022,931           Current liabilities         10,189,711         12,022,931           Payables         491,745         131,610           Income in advance         2,095,787         2,683,181           Contract liabilities         227,129         184,325           Employee benefits         227,129         184,325           Lease liabilities         247,415         204,998           Total current liabilities         3,849,501         3,989,539           Employee benefits         3,849,501         3,989,539           Employee benefits         143,375         368,427           Total current liabilities         143,375         368,427           Total non-current liabilities         198,148         412,106           Total liabilities         4,047,648         4,401,645           Net Assets         6,142,063         7,621,286           Equity         Equity         Equity         Equity	Non-current assets		
Right of Use Asset         347,453         522,804           Total non-current assets         8,904,844         9,868,415           Total assets         10,189,711         12,022,931           Current liabilities         491,745         131,610           Payables         491,745         131,610           Income in advance         2,095,787         2,683,181           Contract liability         787,425         785,425           Employee benefits         227,129         184,325           Lease liabilities         247,415         204,998           Total current liabilities         3,849,501         3,989,539           Employee benefits         54,773         43,679           Total current liabilities         143,375         368,427           Total non-current liabilities         198,148         412,066           Total liabilities         4,047,648         4,401,645           Net Assets         6,142,063         7,621,286           Equity         5473         542,1266	Financial assets	8,422,986	9,213,031
Total non-current assets         8,904,844         9,868,415           Total assets         10,189,711         12,022,931           Current liabilities         10         10           Payables         491,745         131,610           Income in advance         2,095,787         2,683,181           Contract liability         787,425         785,425           Employee benefits         227,129         184,325           Lease liabilities         247,415         204,998           Total current liabilities         3,849,501         3,989,539           Employee benefits         54,773         43,679           Lease liabilities         143,375         368,427           Total non-current liabilities         198,148         412,106           Total liabilities         4,047,648         4,401,645           Net Assets         6,142,063         7,621,286	Property, plant and equipment	134,405	132,580
Total assets         10,189,711         12,022,931           Current liabilities         131,610           Payables         491,745         131,610           Income in advance         2,095,787         2,683,181           Contract liability         787,425         785,425           Employee benefits         227,129         184,325           Lease liabilities         247,415         204,998           Total current liabilities         3,849,501         3,989,539           Employee benefits         54,773         43,679           Lease liabilities         143,375         368,427           Total non-current liabilities         198,148         412,106           Total liabilities         4,047,648         4,401,645           Net Assets         6,142,063         7,621,286	Right of Use Asset	347,453	522,804
Current liabilities         Payables       491,745       131,610         Income in advance       2,095,787       2,683,181         Contract liability       787,425       785,425         Employee benefits       227,129       184,325         Lease liabilities       247,415       204,998         Total current liabilities       3,849,501       3,989,539         Employee benefits       54,773       43,679         Lease liabilities       143,375       368,427         Total non-current liabilities       198,148       412,106         Total liabilities       4,047,648       4,401,645         Net Assets       6,142,063       7,621,286         Equity       547,543       542,723	Total non-current assets	8,904,844	9,868,415
Payables         491,745         131,610           Income in advance         2,095,787         2,683,181           Contract liability         787,425         785,425           Employee benefits         227,129         184,325           Lease liabilities         247,415         204,998           Total current liabilities         3,849,501         3,989,539           Employee benefits         54,773         43,679           Lease liabilities         143,375         368,427           Total non-current liabilities         198,148         412,106           Total liabilities         4,047,648         4,401,645           Net Assets         6,142,063         7,621,286           Equity         3,349,501         3,349,501         3,349,501	Total assets	10,189,711	12,022,931
Income in advance       2,095,787       2,683,181         Contract liability       787,425       785,425         Employee benefits       227,129       184,325         Lease liabilities       247,415       204,998         Total current liabilities       3,849,501       3,989,539         Employee benefits       54,773       43,679         Lease liabilities       143,375       368,427         Total non-current liabilities       198,148       412,106         Total liabilities       4,047,648       4,401,645         Net Assets       6,142,063       7,621,286         Equity       54,773       54,726	Current liabilities		
Contract liability       787,425       785,425         Employee benefits       227,129       184,325         Lease liabilities       247,415       204,998         Total current liabilities       3,849,501       3,989,539         Employee benefits       54,773       43,679         Lease liabilities       143,375       368,427         Total non-current liabilities       198,148       412,106         Total liabilities       4,047,648       4,401,645         Net Assets       6,142,063       7,621,286         Equity       54,773       54,723	Payables	491,745	131,610
Employee benefits227,129184,325Lease liabilities247,415204,998Total current liabilities3,849,5013,989,539Employee benefits54,77343,679Lease liabilities143,375368,427Total non-current liabilities198,148412,106Total liabilities4,047,6484,401,645Net Assets6,142,0637,621,286Equity	Income in advance	2,095,787	2,683,181
Lease liabilities247,415204,998Total current liabilities3,849,5013,989,539Employee benefits54,77343,679Lease liabilities143,375368,427Total non-current liabilities198,148412,106Total liabilities4,047,6484,401,645Net Assets6,142,0637,621,286Equity54,57354,773	Contract liability	787,425	785,425
Total current liabilities3,849,5013,989,539Employee benefits54,77343,679Lease liabilities143,375368,427Total non-current liabilities198,148412,106Total liabilities4,047,6484,401,645Net Assets6,142,0637,621,286EquityIntersection100,000	Employee benefits	227,129	184,325
Employee benefits54,77343,679Lease liabilities143,375368,427Total non-current liabilities198,148412,106Total liabilities4,047,6484,401,645Net Assets6,142,0637,621,286Equity	Lease liabilities	247,415	204,998
Lease liabilities143,375368,427Total non-current liabilities198,148412,106Total liabilities4,047,6484,401,645Net Assets6,142,0637,621,286Equity	Total current liabilities	3,849,501	3,989,539
Total non-current liabilities198,148412,106Total liabilities4,047,6484,401,645Net Assets6,142,0637,621,286EquityInstruction of the second seco	Employee benefits	54,773	43,679
Total liabilities       4,047,648       4,401,645         Net Assets       6,142,063       7,621,286         Equity	Lease liabilities	143,375	368,427
Net Assets6,142,0637,621,286Equity	Total non-current liabilities	198,148	412,106
Equity	Total liabilities	4,047,648	4,401,645
	Net Assets	6,142,063	7,621,286
Retained earnings 6,142,063 7,621,286	Equity		
	Retained earnings	6,142,063	7,621,286

Other comprehensive income for the year Balance at 30 June 2021	7,621,286	7,621,286
Other comprehensive income for the year		
Surplus for the six month period	2,286,276	2,286,276
Balance at 31 December 2020 - Restated	5,335,010	5,335,010
Lung Foundation Australia statement of changes in equity For the year ended 30 June 2022	Retained Surplus [\$]	Total [\$]
Cash and cash equivalents at the end of the financial year	771,584	870,365
Cash and cash equivalents at the beginning of the financial year	870,365	1,334,516
Net increase/(decrease) in cash and cash equivalents held	(98,781)	(464,151)
Net cash flows used in financing activities	(233,792)	(147,363)
Payment of lease liabilities	(233,792)	(147,363)
Cash flows from financing activities		
Net cash flows used in investing activities	(474,091)	(2,263,696)
Proceeds from sale of financial assets	0	2,728,343
Purchase of financial assets	(405,000)	(4,982,542)
Purchase of property, plant and equipment	(69,091)	(9,497)
Cash flows from investing activities		
Net cash flows from operating activities	609,102	1,946,908
Finance Costs paid	(27,704)	(17,315)
Interest received	9,822	9,023
Dividends received	646,066	71,784
Payments to suppliers and employees	(8,974,280)	(4,949,679)
Receipts from customers	6,186,197	6,255,190
Receipts from government	2,769,001	577,905
Cash flows from operating activities	[4]	
Lung Foundation Australia statement of cash flows For the year ended 30 June 2022	12 months to 30 June 2022 [\$]	6 months to 30 June 2021 [\$]

# How you can help



# Leave a gift in your Will

A gift in your will is a gift of hope to future generations. A hope that one day a cure can be found and that Australians living with lung disease and lung cancer will be able to live their best lives. Every gift, no matter what the size, makes a powerful difference to the future of millions of current and future Australians living with devastating lung conditions.

# Give a regular gift

Regular giving is a simple and effective way to help make a real difference to our work in the areas of awareness, education, support and research into lung disease and lung cancer. Your regular monthly donation helps us plan for the future. The security we receive through ongoing funding allows us to reduce administration costs, in turn ensuring that every donated dollar goes even further.

# Philanthropy and partnerships

We are proud to partner with philanthropists, companies, trusts and foundations whose values are aligned with ours. We believe that all partnerships should have impact. We work closely with our corporate and philanthropic partners to make sure that their investments continue to deliver on their objectives.

### Become a member

You don't need to be a member of Lung Foundation Australia to access any of the information or services we offer. However, by becoming a member you provide us with much-needed ongoing support. In return, you will join a nationwide community of health professionals, researchers and individuals all striving to improve care for the seven million Australians impacted by lung disease and lung cancer.

# **Lung** Foundation Australia

# f y in 😁 🎯

Lung Foundation Australia, Level 2, 11 Finchley Street, Milton QLD 4064 PO Box 1949, Milton QLD 4064 enquiries@lungfoundation.com.au lungfoundation.com.au Free call 1800 654 301



